In short
A new drug called SYN321 is currently being studied in clinical trials for the treatment of knee osteoarthritis. This innovative medication is administered through intra-articular injections directly into the knee joint. The ongoing research aims to evaluate the safety, tolerability, and potential effectiveness of SYN321 in providing relief for patients suffering from this common and often debilitating condition.
At a glance
- Drug Name
- SYN321
- Condition Treated
- Knee Osteoarthritis
- Administration Method
- Intra-articular injection
- Main Study Objectives
- Safety, tolerability, systemic exposure, preliminary efficacy
- Study Duration
- 56 days after injection
- Key Measurements
- Daily pain levels, knee function, quality of life, use of rescue medication
- Potential Effects
- Local analgesic, anti-inflammatory, potential lubricating effect
What is SYN321?
SYN321 is a new medication being developed to treat knee osteoarthritis (KOA). It is currently undergoing clinical trials to assess its safety and effectiveness. SYN321 is designed to be administered as an intra-articular injection, which means it's injected directly into the knee joint.
How Does SYN321 Work?
SYN321 is described as having a local analgesic (pain-relieving) and anti-inflammatory effect. It may also have a potential lubricating effect on the knee joint. The active substance in SYN321 is related to diclofenac, which is a well-known non-steroidal anti-inflammatory drug (NSAID). However, SYN321 has been specially formulated to be injected directly into the knee, potentially providing targeted relief for osteoarthritis symptoms.
Clinical Trial Details
The clinical trial for SYN321 is a Phase 1/2a study, which means it's in the early stages of testing in humans. Here are some key details about the trial:
- It's a prospective, double-blinded, randomized, placebo-controlled study. This means that participants will be randomly assigned to receive either SYN321 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is complete.
- The main goal is to evaluate the safety and tolerability of SYN321 after a single injection into the knee joint.
- The study will also look at how the body processes SYN321 and assess its preliminary effectiveness in treating knee osteoarthritis symptoms.
Who Can Participate in the SYN321 Trial?
The trial has specific criteria for who can participate. Some key inclusion criteria are:
- Adults aged 40 to 79 years
- Diagnosed with knee osteoarthritis
- Experiencing moderate to severe knee pain (rated 4-8 on a 0-10 scale)
- Body Mass Index (BMI) between 18.5 and 35.0 kg/m²
There are also several exclusion criteria, including certain medical conditions, recent knee injections or surgeries, and use of specific medications. It's important to note that these criteria are designed to ensure the safety of participants and the reliability of the study results.
Potential Benefits and Risks
While the potential benefits of SYN321 are still being studied, it may offer relief from knee osteoarthritis symptoms, including pain and inflammation. However, as with any medical treatment, there may be risks involved. The study is designed to carefully monitor for any side effects or adverse reactions.
What to Expect During the Trial
If you participate in the trial, you can expect:
- A single injection of either SYN321 or a placebo into your knee joint
- Regular check-ups and monitoring, including blood tests, urine tests, and electrocardiograms (ECGs)
- Daily self-assessments of your knee pain using a numerical rating scale
- Questionnaires about your knee function and quality of life
- Restrictions on using certain pain medications during the study period
The trial will last for 56 days after the injection, during which time you'll be closely monitored for any changes in your condition or any side effects.